Solid Biosciences (SLDB) Cash from Financing Activities (2017 - 2026)

Solid Biosciences has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $239.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $239.0 million, up 25.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $243.7 million (up 18.94% YoY), and the FY2025 annual result was $194.4 million, up 58.81% from the prior year.
• Cash from Financing Activities came in at $239.0 million for Q1 2026 at Solid Biosciences, up from $5.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $239.0 million in Q1 2026 to a low of -$1.6 million in Q2 2025.
• The 5-year median for Cash from Financing Activities is $4.1 million (2024), against an average of $45.1 million.
• Peak annual rise in Cash from Financing Activities reached 113137.88% in 2022, while the deepest fall reached 133.33% in 2022.
• Solid Biosciences' Cash from Financing Activities stood at $74.7 million in 2022, then plunged by 99.32% to $505000.0 in 2023, then soared by 1274.26% to $6.9 million in 2024, then decreased by 25.89% to $5.1 million in 2025, then jumped by 4547.62% to $239.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $239.0 million (Q1 2026), $5.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.